Based on these findings, we evaluated the influence of IL-6 on anti-angiogenic and anti-tumor efficacies of Bev using an in vitro OCCC model to reveal potential molecular mechanisms, and further examined the association of IL-6 expression with that of the pro-angiogenic factor Ang1 among OCCC patients to help identify good candidates for Bev treatment. This evidence concerns the gene ANGPT1 and neoplasm.